SRTA at a glance
Strata Critical Medical, Inc. (SRTA, SEC CIK 1779128) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and Form 4 insider filings as recently as September 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Strata Critical Medical, Inc. (SRTA) reported revenue of $197.1 million (down 20.7% from FY2024) and net income of $41.3 million. Diluted EPS was $0.50.
- As of June 30, 2026, 24 institutional investment managers tracked by SignalX reported holding Strata Critical Medical, Inc. (SRTA) shares worth $126.1 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Love Reginald on August 10, 2026 of 5,091 shares at $5.75 per share.
- In the last 90 days, SRTA insiders reported 0 open-market purchases ($0) and 1 open-market sale ($29K) on Form 4, a net sale of $29K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $197.1M
- −20.7% vs prior year
- Insiders · 90 days
- 0 buys · 1 sell
- Net −$29K
- 13F holders
- 24 funds
- $126.1M · −2 vs prior quarter
- Latest 8-K
- Aug 4, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue and YoY change not provided in supplied MD&A excerpt
- Profitability and margin percentages not provided in supplied MD&A excerpt
- Segment performance unavailable; Logistics and Clinical segment descriptions only
- Passenger sale generated $70.2M net proceeds; additional consideration up to $35.0M
- 2026 acquisitions totaled $39.2M upfront cash consideration; donor supply flattening flagged as headwind
Risk Factors
- No material risk-factor changes from December 31, 2025 Form 10-K
- Trading-price risk from business results differing materially from expectations
- Forward-looking-statement risk from actual results differing materially from projections
- Acquisition-related equity issuance: 742,060 shares issued for HLT-NRP on June 24, 2026
AI summary of the SRTA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release issued August 4, 2026
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders elected William A. Heyburn and Andrew Lauck as Class II directors through the 2029 annual meeting
- Heyburn received 46,050,902 votes for, while Lauck received 39,525,159, indicating materially stronger support for Heyburn
Item 2.02: Results of Operations and Financial Condition
- Q1 2026 results for period ended March 31, 2026, announced May 6, 2026
- Financial details and management commentary contained in furnished Exhibit 99.1 press release
AI summaries of SRTA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SRTA
Don't miss the next SRTA filing
- Alerts as it files. A push when SRTA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SRTA, by share count.
- Ask anything. An AI agent that reads every SRTA filing and answers with sources.
SRTA alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Tomkiel Melissa M. | A | Sep 24, 2026 | 177,858 | - |
| Heyburn William A. | F | Sep 24, 2026 | 98,356 | $5.27 |
| Tomkiel Melissa M. | F | Sep 24, 2026 | 90,797 | $5.27 |
| Heyburn William A. | A | Sep 24, 2026 | 177,858 | - |
| Wunsch Scott M | F | Sep 8, 2026 | 5,711 | $5.31 |
| Verdetto Louis R. | F | Sep 8, 2026 | 5,697 | $5.31 |
| Cohen Amir | F | Sep 8, 2026 | 4,645 | $5.31 |
| Tomkiel Melissa M. | F | Sep 8, 2026 | 29,730 | $5.31 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $248.7M | $197.1M |
| Gross Profit | - | $29.6M | $41.1M |
| Operating Income | - | -$33.9M | -$22.4M |
| Net Income | - | -$27.3M | $41.3M |
| Gross Margin | - | 11.9% | 20.9% |
| Op. Margin | - | -13.6% | -11.3% |
| Net Margin | - | -11.0% | 21.0% |
| Balance Sheet | |||
| Total Assets | - | $256.7M | $325.5M |
| Equity | - | $221.9M | $279.1M |
| ROE | - | -12.3% | 14.8% |
| Per Share | |||
| EPS | $-0.76 | $-0.35 | $0.50 |
| Cash Flow | |||
| Operating CF | - | -$2.5M | -$48.9M |
| CapEx | $2.1M | $30.9M | $9.6M |
Source: XBRL data in Strata Critical Medical, Inc. (SRTA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate SRTA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 24 | $126.1M |
| Q1 2026 | 26 | $116.3M |
| Q4 2025 | 24 | $133.8M |
| Q3 2025 | 25 | $137.1M |
| Q2 2025 | 23 | $93.3M |
| Q1 2025 | 19 | $51.2M |
| Q4 2024 | 16 | $72.0M |
| Q3 2024 | 13 | $35.0M |
- Citigroup+430.2K (+445%)
- BlackRock+267.2K (+6%)
- State Street Corp+178.3K (+13%)
- Dimensional Fund Advisors+121.5K (+8%)
- BNY Mellon+62.0K (+6%)
- ARK Investment Management−4.72M (-63%)
- Morgan Stanley−72.5K (-15%)
- JPMorgan Chase & Co−3.9K (-1%)
- Bank of America Corp−3.5K (-2%)
- Prudential Financial−1.3K (-7%)
- Citadel Advisors LLC−372.9K
- U.S. Bancorp−71
Source: 13F-HR filings on SEC EDGAR (aggregated from 170 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SRTA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 25, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| SC 13G | Jun 17, 2026 | - | - | |
| 4 | Jun 10, 2026 | - | - |
Related Health Care companies
- DCGO · DocGo Inc.Services-Health Services
- WGS · GeneDx Holdings Corp.Services-Health Services
- INNV · InnovAge Holding Corp.Services-Health Services
- LFST · LifeStance Health Group, Inc.Services-Health Services
- OMDA · Omada Health, Inc.Services-Health Services
- PNTG · Pennant Group, Inc.Services-Health Services
- PRVA · Privia Health Group, Inc.Services-Health Services
- TALK · Talkspace, Inc.Services-Health Services
SRTA SEC filings: frequently asked questions
Are SRTA insiders buying or selling?
In the last 90 days, Strata Critical Medical, Inc. (SRTA) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $29,273 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold SRTA stock?
As of June 30, 2026, the largest Strata Critical Medical, Inc. (SRTA) holders among the 13F filers tracked by SignalX were Third Point LLC ($26.4 million), BlackRock ($25.5 million), Vanguard Capital Management LLC ($15.2 million), ARK Investment Management ($14.4 million), Dimensional Fund Advisors ($9.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SRTA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Strata Critical Medical, Inc. (SRTA) reported revenue of $197.1 million (down 20.7% from FY2024) and net income of $41.3 million. Diluted EPS was $0.50. The figures come from the XBRL data in the 10-K.
What did SRTA report in its latest 8-K?
Strata Critical Medical, Inc. (SRTA) filed an 8-K on August 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results for quarter ended June 30, 2026.
What are the latest SRTA SEC filings?
Strata Critical Medical, Inc. (SRTA) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 4, 2026, an 8-K current report on August 4, 2026 and a Form 4 insider filing on September 25, 2026.
What is SRTA's SEC CIK number?
Strata Critical Medical, Inc. (SRTA)'s SEC Central Index Key (CIK) is 1779128. EDGAR lists every SRTA filing under that number.
Ask anything about SRTA
The research agent reads SRTA's filings, financials, insider trades and 13F holders, then answers with sources.